Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist

Abstract We report the discovery of strong HNF4α agonists and their use to uncover a previously unknown pathway by which HNF4α controls the level of fat storage in the liver. This involves the induction of lipophagy by dihydroceramides, the synthesis and secretion of which is controlled by genes ind...

Full description

Bibliographic Details
Main Authors: Seung-Hee Lee, Vimal Veeriah, Fred Levine
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-021-03862-x
id doaj-e294ac4cd62f4a9f87cb27d51d5aadbf
record_format Article
spelling doaj-e294ac4cd62f4a9f87cb27d51d5aadbf2021-06-13T11:05:55ZengNature Publishing GroupCell Death and Disease2041-48892021-06-0112611810.1038/s41419-021-03862-xLiver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonistSeung-Hee Lee0Vimal Veeriah1Fred Levine2SBP Medical Discovery InstituteSBP Medical Discovery InstituteSBP Medical Discovery InstituteAbstract We report the discovery of strong HNF4α agonists and their use to uncover a previously unknown pathway by which HNF4α controls the level of fat storage in the liver. This involves the induction of lipophagy by dihydroceramides, the synthesis and secretion of which is controlled by genes induced by HNF4α. The HNF4α activators are N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT), which are structurally related to the known drugs alverine and benfluorex, which we previously showed to be weak HNF4α activators. In vitro, NCT and NFT induced fat clearance from palmitate-loaded cells. In DIO mice, NCT led to recovery of hepatic HNF4α expression and reduction of steatosis. Mechanistically, increased dihydroceramide production and action downstream of HNF4α occurred through increased expression of HNF4α downstream genes, including SPNS2 and CYP26A1. NCT was completely nontoxic at the highest dose administered and so is a strong candidate for an NAFLD therapeutic.https://doi.org/10.1038/s41419-021-03862-x
collection DOAJ
language English
format Article
sources DOAJ
author Seung-Hee Lee
Vimal Veeriah
Fred Levine
spellingShingle Seung-Hee Lee
Vimal Veeriah
Fred Levine
Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist
Cell Death and Disease
author_facet Seung-Hee Lee
Vimal Veeriah
Fred Levine
author_sort Seung-Hee Lee
title Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist
title_short Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist
title_full Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist
title_fullStr Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist
title_full_unstemmed Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist
title_sort liver fat storage is controlled by hnf4α through induction of lipophagy and is reversed by a potent hnf4α agonist
publisher Nature Publishing Group
series Cell Death and Disease
issn 2041-4889
publishDate 2021-06-01
description Abstract We report the discovery of strong HNF4α agonists and their use to uncover a previously unknown pathway by which HNF4α controls the level of fat storage in the liver. This involves the induction of lipophagy by dihydroceramides, the synthesis and secretion of which is controlled by genes induced by HNF4α. The HNF4α activators are N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT), which are structurally related to the known drugs alverine and benfluorex, which we previously showed to be weak HNF4α activators. In vitro, NCT and NFT induced fat clearance from palmitate-loaded cells. In DIO mice, NCT led to recovery of hepatic HNF4α expression and reduction of steatosis. Mechanistically, increased dihydroceramide production and action downstream of HNF4α occurred through increased expression of HNF4α downstream genes, including SPNS2 and CYP26A1. NCT was completely nontoxic at the highest dose administered and so is a strong candidate for an NAFLD therapeutic.
url https://doi.org/10.1038/s41419-021-03862-x
work_keys_str_mv AT seungheelee liverfatstorageiscontrolledbyhnf4athroughinductionoflipophagyandisreversedbyapotenthnf4aagonist
AT vimalveeriah liverfatstorageiscontrolledbyhnf4athroughinductionoflipophagyandisreversedbyapotenthnf4aagonist
AT fredlevine liverfatstorageiscontrolledbyhnf4athroughinductionoflipophagyandisreversedbyapotenthnf4aagonist
_version_ 1721380204958449664